These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 24879665)

  • 1. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
    DelDot ME; Lipman J; Tett SE
    Br J Clin Pharmacol; 2004 Sep; 58(3):259-68. PubMed ID: 15327585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
    Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.
    Roger C; Muller L; Wallis SC; Louart B; Saissi G; Lipman J; Lefrant JY; Roberts JA
    J Antimicrob Chemother; 2016 Feb; 71(2):464-70. PubMed ID: 26538503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
    J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.
    Cirillo I; Vaccaro N; Balis D; Redman R; Matzke GR
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1187-93. PubMed ID: 21199922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
    Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL
    Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.
    Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F
    J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration.
    Malone ME; Corrigan OI; Kavanagh PV; Gowing C; Donnelly M; D'Arcy DM
    Int J Antimicrob Agents; 2013 Oct; 42(4):335-42. PubMed ID: 23920093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF).
    Hidaka S; Goto K; Hagiwara S; Iwasaka H; Noguchi T
    Yakugaku Zasshi; 2010 Jan; 130(1):87-94. PubMed ID: 20046071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
    Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
    Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
    Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study.
    Markou N; Fousteri M; Markantonis SL; Zidianakis B; Hroni D; Boutzouka E; Baltopoulos G
    J Antimicrob Chemother; 2012 Oct; 67(10):2459-62. PubMed ID: 22790220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.
    Spooner AM; Deegan C; D'Arcy DM; Gowing CM; Donnelly MB; Corrigan OI
    BMC Clin Pharmacol; 2011 Aug; 11():11. PubMed ID: 21816053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.